YIH
NGM

Y-Intercept (HK)’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Y-Intercept (HK)’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,475
Closed -$62.6K – 1634
2022
Q4 		$62.6K Buy
+12,475
New +$78.2K 0.01% 909

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Y-Intercept (HK)'s NGM Position: Q1 2023 in Review

Y-Intercept (HK) sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2023, closing a stake of 12,475 shares — an estimated $62.6K sold.

Y-Intercept (HK) first reported a position in NGM in Q4 2022 and held it in 1 quarter. The position peaked at $62.6K in Q4 2022. 122 funds tracked by Wall St. Rank hold NGM as of Q1 2023.

  • Y-Intercept (HK) reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Y-Intercept (HK) sold 12,475 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $62.6K.
  • Y-Intercept (HK) first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Y-Intercept (HK)'s NGM Biopharmaceuticals, Inc. Common Stock position peaked at $62.6K in Q4 2022.
  • 122 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Y-Intercept (HK)'s 13F filing for Q1 2023, filed 9 May 2023.